Status:
COMPLETED
Enzastaurin Versus Lomustine in Glioblastoma
Lead Sponsor:
Eli Lilly and Company
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).
Eligibility Criteria
Inclusion
- Patient presents with histologically confirmed diagnosis of brain cancer (specifically glioblastoma multiforme).
- Your cancer has returned following therapy.
- Patient may have undergone prior surgery to remove cancer.
- Patient must be able to care for self.
Exclusion
- Have a second type of cancer (except adequately treated basal cell carcinoma of the skin). Patient who has had another cancer in the past, must be free of cancer for more than 2 years.
- Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of entry.
- Patients receiving medication for seizures must discontinue 14 days prior to enrolling.
- Cannot be on blood thinning medication at study enrollment.
- Cannot be on other medicines to prevent cancer at study enrollment.
- Patients are not allowed to enter the study if they have previously taken Enzastaurin, Lomustine and/or Bevacizumab.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
397 Patients enrolled
Trial Details
Trial ID
NCT00295815
Start Date
January 1 2006
End Date
May 1 2014
Last Update
September 12 2019
Active Locations (98)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States, 85013
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tucson, Arizona, United States, 85724
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Berkeley, California, United States, 94704
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Los Angeles, California, United States, 90048